Clinical Trial Update: SHR6390 Plus Nab-paclitaxel and Gemcitabine in Advanced/Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of SHR6390 with nab-paclitaxel and gemcitabine in advanced/metastatic pancreatic cancer is underway with unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• SHR6390 (SHR6390)

Snippet

Sponsor: Ruijin Hospital | Conditions: Pancreatic Cancer | Phase 2 | Status: UNKNOWN